Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (2) , 207-210
- https://doi.org/10.1023/a:1008372404504
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogsJournal of Medicinal Chemistry, 1993
- Reporting results of cancer treatmentCancer, 1981
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961